LENZ Therapeutics Future Growth
Future criteria checks 2/6
LENZ Therapeutics is forecast to grow earnings and revenue by 41% and 68.6% per annum respectively. EPS is expected to grow by 45.5% per annum. Return on equity is forecast to be -35.8% in 3 years.
Key information
41.0%
Earnings growth rate
45.5%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | 68.6% |
| Future return on equity | -35.8% |
| Analyst coverage | Good |
| Last updated | 08 Nov 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 52 | -63 | -57 | -68 | 6 |
| 12/31/2025 | 9 | -73 | -76 | -69 | 7 |
| 12/31/2024 | N/A | -49 | -43 | -57 | 7 |
| 9/30/2024 | N/A | -61 | -72 | -71 | N/A |
| 6/30/2024 | N/A | -69 | -74 | -74 | N/A |
| 3/31/2024 | N/A | -74 | -72 | -72 | N/A |
| 12/31/2023 | N/A | -70 | -60 | -60 | N/A |
| 9/30/2023 | N/A | -56 | -47 | -47 | N/A |
| 12/31/2022 | 15 | -11 | -4 | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LENZ is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LENZ is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LENZ is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LENZ's revenue (68.6% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: LENZ's revenue (68.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LENZ is forecast to be unprofitable in 3 years.